Increased Plasma ApoM Levels in Hepatocellular Carcinoma Patients
Author Information
Author(s): Jiang Jingting, Zhang Xiaoying, Wu Changping, Qin Xihu, Luo Guanghua, Deng Haifeng, Lu Minyang, Xu Bin, Li Min, Ji Mei, Xu Ning
Primary Institution: The Third Affiliated Hospital of Suzhou University
Hypothesis
To determine plasma apolipoprotein M (apoM) levels and other lipid profiles in hepatocellular carcinoma (HCC) patients compared to other chronic liver diseases and normal subjects.
Conclusion
Increased plasma apoM levels were found in HCC patients, while serum triglycerides, apoAI, HDL-C, and Lp(a) were significantly decreased.
Supporting Evidence
- Serum levels of triglycerides, HDL-cholesterol, apoAI, and Lp(a) were significantly lower in HCC patients than in normal subjects.
- Plasma apoM levels in HCC patients were significantly increased compared to normal subjects.
- Decreased serum TG, apoAI, HDL-C, and Lp(a) may reflect liver damage in HCC patients.
- Plasma apoM levels were even higher in chronic hepatitis and cirrhosis patients.
Takeaway
This study found that people with liver cancer have higher levels of a specific protein called apoM, but lower levels of some fats in their blood compared to healthy people.
Methodology
The study involved 36 HCC patients, 68 chronic hepatitis patients, 29 liver cirrhosis patients, and 64 normal controls, with serum lipids and apoM levels measured using conventional methods.
Limitations
The clinical significance of increased plasma apoM levels in relation to HCC is not clear.
Participant Demographics
36 HCC patients (29 men, 7 women, mean age 57), 68 chronic hepatitis patients (53 men, 15 women, mean age 37), 29 liver cirrhosis patients (21 men, 8 women, mean age 52), and 64 normal subjects (44 men, 20 women, mean age 43).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website